Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Bone marrow suppression

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    80 result(s) found for: Bone marrow suppression. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2019-003771-19 Sponsor Protocol Number: 2019-100 Start Date*: 2019-11-19
    Sponsor Name:Aarhus Universitetshospital
    Full Title: The effect of improved insulin sensitivity on bone turnover markers and bone biomechanical properties in persons with type 2 diabetes mellitus
    Medical condition: Type 2 diabetes mellitus Diabetic bone disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-000157-41 Sponsor Protocol Number: UoL001343 Start Date*: 2019-06-07
    Sponsor Name:The University of Liverpool
    Full Title: NEO21-RS: A phase II randomised study of the cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with oestrogen suppression therapy versus oestrogen suppression therapy alone as neoadj...
    Medical condition: ER-positive, HER2-negative breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070577 Oestrogen receptor positive breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2006-002669-38 Sponsor Protocol Number: 0822-016 Start Date*: 2006-12-07
    Sponsor Name:Merck & Co Inc.
    Full Title: A Phase II Study to Assess the Safety, Tolerability, and Efficacy of MK-0822 (Cathepsin-K Inhibitor) in the Treatment of Women with Breast Cancer and Established Bone Metastases (MBD)
    Medical condition: Metastatic Bone Disease (MBD)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10027452 Metastases to bone LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) NO (Completed) DK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-003705-27 Sponsor Protocol Number: MK URO 4 Start Date*: 2007-09-27
    Sponsor Name:AKH Vienna
    Full Title: RANDOMIZED, CONTROLLED BIOMARKER STUDY EVALUATING THE ANTI-ANGIOGENIC ACTIVITY OF SUNITINIB IN HORMONE REFRACTORY PROSTATE CANCER PATIENTS TREATED BY DOCETAXEL
    Medical condition: hormone refraktory prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2016-004804-77 Sponsor Protocol Number: 1262_OPBG_2018 Start Date*: 2018-07-10
    Sponsor Name:BAMBINO GESU' CHILDREN'S HOSPITAL
    Full Title: A prospective study to assess safety and efficacy of the use of bone-marrow derived MESenchymal stromal cells as immunomodulatory therapy for children and young adults with severe and difficult-to-...
    Medical condition: severe multi-relapsing or steroid-dependent INS.
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-002194-18 Sponsor Protocol Number: CA209-9P9 Start Date*: 2018-03-15
    Sponsor Name:Medical Center - University of Freiburg
    Full Title: Phase 1/2 Trial to determine the Response Rate of Nivolumab in Acute Myeloid Leukemia (AML) relapse after Allogeneic Hematopoietic Cell Transplantation (allo-HCT)
    Medical condition: Acute myeloid leukemia relapse after allo-HCT
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10001941 AML LLT
    20.0 100000004864 10066572 AML progression LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-023783-41 Sponsor Protocol Number: E7080-G000-303 Start Date*: 2011-07-05
    Sponsor Name:Eisai Limited
    Full Title: A Multicenter, Randomized, Double- Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I- Refractory Differentiated Thyroid Cancer
    Medical condition: 131I-refractory differentiated thyroid cancer (DTC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055107 Thyroid cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Completed) PT (Completed) GB (Completed) DE (Completed) ES (Completed) PL (Completed) DK (Completed) AT (Completed) IT (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2010-024307-27 Sponsor Protocol Number: LUMC2010-03 Start Date*: 2011-11-01
    Sponsor Name:Leiden University Medical Center
    Full Title: TREATMENT WITH CMV PP65-SPECIFIC T CELLS GENERATED BY USE OF A CMV PP65 PROTEIN-SPANNING PEPTIDE POOL IN PATIENTS WITH CMV REACTIVATION OR CMV DISEASE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
    Medical condition: CMV reactivation after allogeneic stem cell transplantation
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-023437-30 Sponsor Protocol Number: A7281006 Start Date*: 2011-09-29
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-00547659 IN SUBJECTS WITH CROHN’S DISEASE(OPERA)
    Medical condition: Crohn's Disease
    Disease: Version SOC Term Classification Code Term Level
    16.1 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) BE (Completed) SE (Completed) AT (Completed) DE (Completed) PT (Prematurely Ended) NO (Completed) NL (Completed) ES (Completed) PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2009-017596-26 Sponsor Protocol Number: RESTORE Start Date*: 2010-03-10
    Sponsor Name:G.O.N.O. - GRUPPO ONCOLOGICO NORD OVEST
    Full Title: Terapia di II linea con Docetaxel + Lanreotide in pazienti con carcinoma prostatico metastatico ormonorefrattario e in progressione in corso di chemioterapia di I linea con Docetaxel. Studio di fas...
    Medical condition: METASTATIC HORMONREFRACTORY PROSTATE CARCINOMA
    Disease: Version SOC Term Classification Code Term Level
    9.1 10007453 LLT
    Population Age: Elderly Gender: Male
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-003237-33 Sponsor Protocol Number: HO112 Start Date*: 2013-11-21
    Sponsor Name:HOVON Foundation
    Full Title: Treatment of severe GVHD after allogeneic hematopoietic stem cell transplanatation with MSCs and steroid versus steroids alone. A prospective double-blind placebo-controlled randomized phase III t...
    Medical condition: Graft Versus Host Disease
    Disease: Version SOC Term Classification Code Term Level
    18.0 10021428 - Immune system disorders 10066260 Acute graft versus host disease PT
    18.0 10021428 - Immune system disorders 10068908 AGVHD LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-006300-27 Sponsor Protocol Number: MC-ASP.6/INF Start Date*: 2009-08-12
    Sponsor Name:medac Gesellschaft für klinische Spezialpräparate mbH
    Full Title: Efficacy and safety of recombinant asparaginase in infants (< 1 year) with previously untreated acute lymphoblastic leukaemia - Phase II Clinical Trial -
    Medical condition: Acute lymphoblastic leukaemia (ALL) is a clonal disease resulting from genetic mutations and transformation of a single early progenitor lymphoid cell. Uncontrolled expansion of leukaemic blasts in...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000844 Acute lymphoblastic leukaemia LLT
    Population Age: Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-006292-20 Sponsor Protocol Number: GS-US-312-0115 Start Date*: 2012-07-20
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination with Bendamustine and Rituximab for Previously Treated Chroni...
    Medical condition: Chronic Lymphocytic Leukemia (CLL)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008958 Chronic lymphocytic leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) ES (Completed) IT (Completed) PL (Completed) CZ (Completed) HU (Completed) DE (Completed) IE (Completed) PT (Completed) GR (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2017-000565-76 Sponsor Protocol Number: MM-121-02-02-10 Start Date*: 2018-04-05
    Sponsor Name:Merrimack Pharmaceuticals, Inc.
    Full Title: SHERBOC: A Double-blind, Placebo-controlled, Phase 2 trial of Seribantumab Plus Fulvestrant in Postmenopausal Women with Hormone Receptor-positive, Heregulin Positive (HRG+), HER2 Negative Metastat...
    Medical condition: Hormone Receptor-positive, Heregulin Positive (HRG+), HER2 Negative Metastatic Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Prematurely Ended) ES (Prematurely Ended) AT (Prematurely Ended) BE (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-003467-19 Sponsor Protocol Number: CLEE011A2404 Start Date*: 2016-12-08
    Sponsor Name:Novartis Pharma AG
    Full Title: COMPLEEMENT-1: An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal wo...
    Medical condition: hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10072737 Advanced breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (GB - no longer in EU/EEA) NL (Completed) HU (Completed) BG (Completed) PT (Completed) GR (Completed) SK (Completed) IT (Completed) CZ (Completed) AT (Completed) ES (Completed) DK (Completed) NO (Completed) PL (Completed) FI (Completed) SI (Completed) RO (Ongoing) LU (Completed)
    Trial results: View results
    EudraCT Number: 2006-003180-31 Sponsor Protocol Number: MC-ASP.5/ALL Start Date*: 2008-07-29
    Sponsor Name:medac GmbH
    Full Title: Comparative efficacy and safety of two asparaginase preparations in children with previously untreated acute lymphoblastic leukaemia
    Medical condition: Acute lymphoblastic leukaemia (ALL) is a clonal disease resulting from genetic mutations and transformation of a single early progenitor lymphoid cell. Uncontrolled expansion of leukaemic blasts in...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000844 Acute lymphoblastic leukaemia LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2009-012007-25 Sponsor Protocol Number: BAY43-9006/14295 Start Date*: 2009-10-21
    Sponsor Name:Bayer AG
    Full Title: A Double-Blind, Randomized Phase III Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer
    Medical condition: Differentiated thyroid cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066136 Huerthle cell carcinoma PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016935 Follicular thyroid cancer PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033701 Papillary thyroid cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) ES (Completed) IT (Completed) NL (Completed) FR (Completed) DK (Completed) SE (Completed) BE (Completed) AT (Completed) SK (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2017-004003-46 Sponsor Protocol Number: RealMM Start Date*: 2018-09-05
    Sponsor Name:DIPARTIMENTO DI BIOTECNOLOGIE MOLECOLARI E SCIENZE PER LA SALUTE-UNIVERISITÀ DI TORINO
    Full Title: A RANDOMIZED, MULTICENTER, OPEN LABEL STUDY COMPARING TWO STANDARD TREATMENTS, BORTEZOMIB-MELPHALAN-PREDNISONE (VMP) VS LENALIDOMIDE-DEXAMETHASONE (Rd) IN AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT...
    Medical condition: Newly diagnosed MM patients = 65 years old or ineligible for autologous stem cell transplant
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-004800-23 Sponsor Protocol Number: RG-17-241 Start Date*: 2018-06-12
    Sponsor Name:University of Birmingham
    Full Title: A comparison of reduced dose total body irradiation (TBI) and cyclophosphamide with fludarabine and melphalan reduced intensity conditioning in adults with acute lymphoblastic leukaemia (ALL) in co...
    Medical condition: Acute Lymphoblastic Leukaemia (ALL)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10000844 Acute lymphoblastic leukaemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2013-003402-40 Sponsor Protocol Number: XL184-401 Start Date*: 2015-06-16
    Sponsor Name:Exelixis, Inc.
    Full Title: A Randomized, Double-blind Study To Evaluate the Efficacy and Safety of Cabozantinib (XL184) at 60 mg/Day Compared to 140 mg/Day in Progressive, Metastatic Medullary Thyroid Cancer Patients
    Medical condition: Progressive Metastatic Medullary Thyroid Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027105 Medullary thyroid cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing) SE (Completed) ES (Ongoing) FR (Completed) PL (Trial now transitioned) HU (Trial now transitioned) HR (Trial now transitioned) IT (Completed) RO (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 13 12:04:09 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA